7 Analysts Have This to Say About G1 Therapeutics
Over the past 3 months, 7 analysts have published their opinion on G1 Therapeutics (NASDAQ:GTHX) stock. These analysts…
HC Wainwright & Co. Reiterates Buy on G1 Therapeutics, Maintains $11 Price Target
HC Wainwright & Co. analyst Edward White reiterates G1 Therapeutics (NASDAQ:GTHX) with a Buy and maintains $11 price target.
Earnings Scheduled For March 1, 2023
Companies Reporting Before The Bell
• Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million.
G1 Therapeutics Q4 EPS $(0.73) Beats $(0.84) Estimate, Sales $10.30M Beat $9.65M Estimate
G1 Therapeutics (NASDAQ:GTHX) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(0.84) by 13.1 percent. This is a 22.34 percent increase over losses of $(0.94) per share from
Needham Maintains Buy on G1 Therapeutics, Lowers Price Target to $18
Needham analyst Gil Blum maintains G1 Therapeutics (NASDAQ:GTHX) with a Buy and lowers the price target from $31 to $18.
Dow Gains Over 300 Points; S&P 500 Up 1%
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining over 300 points on Monday.
The Dow traded up 1.01% to 34,211.29 while the NASDAQ rose 1.52% to 11,896.33. The S&P 500 also rose, gaining, 1.07% to 4,134.24.
Why Frequency Therapeutics Are Trading Lower By 82%? Here Are Other Stocks Moving In Monday’s Mid-Day Session
Gainers
Vallon Pharmaceuticals, Inc. (NASDAQ: VLON) shares jumped 120.5% to $1.02 after jumping over 72% on Friday.
12 Health Care Stocks Moving In Monday’s Intraday Session
Gainers Vallon Pharmaceuticals (NASDAQ:VLON) shares moved upwards by 146.5% to $1.14 during Monday’s regular session. As of 12:30…
Nasdaq Rises 1.5%; G1 Therapeutics Shares Plummet
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 1.5% on Monday.
The Dow traded up 0.96% to 34,193.83 while the NASDAQ rose 1.52% to 11,896.75. The S&P 500 also rose, gaining, 1.03% to 4,132.54.